var data={"title":"Hepatitis A vaccine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hepatitis A vaccine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6308?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hepatitis-a-vaccine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hepatitis A vaccine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=hepatitis-a-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hepatitis A vaccine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178838\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Havrix;</li>\n      <li>VAQTA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178839\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Avaxim;</li>\n      <li>Avaxim-Pediatric;</li>\n      <li>HAVRIX;</li>\n      <li>VAQTA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178849\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Viral)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178840\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immunization:</b> <b>Note:</b> Although it is preferred to use the vaccines according to their approved labeling, Havrix and VAQTA are considered to be interchangeable for booster doses (CDC/ACIP [Fiore 2006]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary immunization: Note:</b> When used for primary immunization, the vaccine should be given at least 2 weeks prior to expected HAV exposure. When used prior to an international adoption, the vaccination series should begin when adoption is being planned, but ideally &ge;2 weeks prior to expected arrival of adoptee (CDC 58[36] 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Manufacturer&rsquo;s labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Avaxim [Canadian product]: IM: 160 units (0.5 mL) with a booster dose of 160 units (0.5 mL) to be given 6 to 36 months following primary immunization</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Havrix: IM: 1440 ELISA units (1 mL) with a booster dose of 1440 ELISA units (1 mL) to be given 6 to 12 months following primary immunization.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">VAQTA: IM: 50 units (1 mL) with a booster dose of 50 units (1 mL) to be given 6-18 months after primary immunization (6 to 12 months if initial dose was with Havrix).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Postexposure prophylaxis (off-label use):</b> Adults without immunity: IM: Administer a single dose as soon as possible following recent exposure to hepatitis A virus (during last 2 weeks) (CDC 56[41] 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178845\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=hepatitis-a-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hepatitis A vaccine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Immunization:</b> <b>Note:</b> Although it is preferred to use the vaccines according to their approved labeling, Havrix and VAQTA are considered to be interchangeable for booster doses (CDC/ACIP [Fiore 2006]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Primary immunization:</b> Advisory Committee on Immunization Practices (ACIP): Children &ge;12 months: All children should receive primary immunization with a two-dose series. The series should be initiated at 12 to 23 months; the two doses should be separated by 6 to 18 months (CDC/ACIP [Fiore 2006]). <b>Note:</b> When used for primary immunization, the vaccine should be given at least 2 weeks prior to expected HAV exposure. When used prior to an international adoption, the vaccination series should begin when adoption is being planned, but ideally &ge;2 weeks prior to expected arrival of adoptee (CDC 58[36] 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturer&rsquo;s labeling</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Avaxim [Canadian product]: Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Avaxim-Pediatric [Canadian product]: Children &ge;12 months and Adolescents &le;15 years: IM: 80 units (0.5 mL) with a booster dose of 80 units (0.5 mL) to be given 6 to 36 months following primary immunization</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Havrix: Children &ge;12 months and Adolescents: IM: 720 ELISA units (0.5 mL) with a booster dose of 720 ELISA units (0.5 mL) to be given 6 to 12 months following primary immunization</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">VAQTA: Children &ge;12 months and Adolescents: IM: 25 units (0.5 mL) with a booster dose of 25 units (0.5 mL) to be given 6 to 18 months after primary immunization (6 to 12 months if initial dose was with HAVRIX)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Postexposure prophylaxis (off-label use): </b> Children and Adolescents without immunity: IM: 0.5 mL once as soon as possible following recent exposure to hepatitis A virus (during last 2 weeks) (CDC 56[41] 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178841\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897460\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897461\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific recommendations provided in manufacturer&rsquo;s labeling. However, data suggest patients with chronic liver disease have a lower antibody response to HAVRIX than healthy subjects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178823\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, suspension [adult, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Havrix: Hepatitis A virus antigen 1440 ELISA units/mL (1 mL) [contains aluminum, neomycin (may have trace amounts); may contain natural rubber/natural latex in prefilled syringe]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">VAQTA: Hepatitis A virus antigen 50 units/mL (1 mL) [contains aluminum, natural rubber/natural latex in packaging]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, suspension [pediatric, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Havrix: Hepatitis A virus antigen 720 ELISA units/0.5 mL (0.5 mL) [contains aluminum, neomycin (may have trace amounts); may contain natural rubber/natural latex in prefilled syringe]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, suspension [pediatric/adolescent, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">VAQTA: Hepatitis A virus antigen 25 units/0.5 mL (0.5 mL) [contains aluminum, natural rubber/natural latex in packaging]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178810\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21082722\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension [pediatric/adolescent]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Avaxim-Pediatric: Hepatitis A virus antigen 80 units/0.5 mL [contains aluminum, polysorbate 80, neomycin (may have trace amounts)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension [adolescent/adult]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Avaxim: Hepatitis A virus antigen 160 units/0.5 mL [contains aluminum, polysorbate 80, neomycin (may have trace amounts)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734111\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the US, the appropriate CDC-approved  Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hep-a.html&amp;token=WTl2LnJRKnPIfGa7i+AXU+p0eEcYV6J6UV9EzpupZDPZ2N8MmgOpx7IZMW3Cnamy6a5evv3w5ME6cgpfOHCVfK8AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=8519\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hep-a.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178827\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For IM administration. The deltoid muscle is the preferred site for injection for older children and adults; administer to the anterolateral aspect of the thigh in infants and young children. Do not administer to the gluteal region; may decrease efficacy. Do not administer intravenously, intradermally, or subcutaneously. Shake well prior to use; discard if the suspension is discolored or does not appear homogenous after shaking, or if there are cracks in the vial or syringe. Do not dilute. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]). To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178826\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hepatitis A virus disease prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For active immunization of persons 12 months and older against disease caused by hepatitis A virus (HAV).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- All children &ge;12 months of age (CDC/ACIP [Fiore 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- All unvaccinated adults requesting protection from HAV infection (CDC/ACIP [Fiore 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Unvaccinated persons with any of the following conditions: Men who have sex with men; injection and non-injection illicit drug users; persons who work with HAV-infected primates or with HAV in a research laboratory setting; persons with chronic liver disease; patients who receive clotting-factor concentrates; persons traveling to or working in countries with high or intermediate levels of endemic HAV infection (CDC/ACIP [Fiore 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Unvaccinated persons who anticipate close personal contact with international adoptee from a country of intermediate to high endemicity of HAV, during their first 60 days of arrival into the United States (eg, household contacts, babysitters) (CDC/ACIP 58[36] 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Vaccination can be a component of hepatitis A outbreak response or as postexposure prophylaxis, as determined by local public health authorities (CDC/ACIP 56[41] 2007; CDC/ACIP [Fiore 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The Canadian National Advisory Committee on Immunization (NACI) also recommends vaccination for the following (NACI 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Persons &ge;6 months at risk for hepatitis A infection (eg, traveling to or from endemic countries) or severe hepatitis A (eg, underlying hepatic disease of idiopathic, metabolic, infectious or cholestatic etiology)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Infants &ge;6 months living with an individual at risk for hepatitis A infection or severe hepatitis A</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Post-exposure prophylaxis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Healthy patients &ge;6 months (vaccine is preferred over immune globulin [Ig])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Within 14 days of exposure of susceptible adults &ge;60 years of age who are household or close contacts of a case (Ig may also be given)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Susceptible individuals with chronic liver disease (Ig should also be administered within 14 days of exposure)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- May be considered in patients who receive repeat administration of plasma-derived clotting factors</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10229825\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">HepA (hepatitis A vaccine) may be confused with HepB (hepatitis B vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HepA (hepatitis A vaccine) may be confused with HPV4 (human papillomavirus vaccine [quadrivalent]; 4vHPV is the correct abbreviation)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Avaxim [Canada and multiple international markets] may be confused with Avastin brand name for bevacizumab [U.S., Canada, and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178817\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or online at <a target=\"_blank\" href=\"https://vaers.hhs.gov/esub/index&amp;token=8m3rK0tzv73hmwLVujPJP0lWL2FxLWQizZTxo5kD83IMEaCGiDnUFaD+0my2cUJQ&amp;TOPIC_ID=8519\" target=\"_blank\">https://vaers.hhs.gov/esub/index</a>.</b>  In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Frequency dependent upon age, product used, and concomitant vaccine administration. In general, headache and injection site reactions were less common in younger children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Drowsiness, headache, irritability</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Decreased appetite</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Erythema at injection site, injection site reaction (soreness, warmth), pain at injection site, swelling at injection site, tenderness at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (&ge;100.4&deg;F [1-5 days postvaccination], &gt;98.6&deg;F [1-14 days postvaccination])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Chills, fatigue, insomnia, malaise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Menstrual disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, gastroenteritis, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Bruising at injection site, induration at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arm pain, back pain, myalgia, stiffness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Otitis media</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Asthma, cough, nasal congestion, nasopharyngitis, pharyngitis, rhinitis, rhinorrhea, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Excessive crying, fever &ge;102&deg;F (1-5 days postvaccination)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, arthralgia, ataxia (cerebellar), bronchiolitis, bronchoconstriction, croup, dehydration, dermatitis, dizziness, dysgeusia, dyspnea, encephalitis, erythema multiforme, eye irritation, flu-like symptoms, Guillain-Barre syndrome, hematoma at injection site, hepatitis, hyperhidrosis, hypersensitivity reaction, hypertonia, hypoesthesia, increased creatine kinase, increased serum transaminases (transient), injection site reaction (nodule), insomnia, jaundice, lymphadenopathy, multiple sclerosis, myelitis, neuropathy, otitis, paresthesia, photophobia, pneumonia, pruritus, rash at injection site, respiratory congestion, seizure, serum sickness-like reaction, syncope, thrombocytopenia, urticaria, vasculitis, vertigo, viral exanthem, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178830\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Immediate and/or severe allergic or hypersensitivity reaction to hepatitis A containing vaccines or any component of the formulation, including neomycin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178814\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]). Canadian product labeling suggests that subcutaneous administration may be considered in exceptional circumstances (eg, patients with thrombocytopenia or at risk for hemorrhage); however, this may convey a higher risk for local reactions (eg, injection site nodule). In healthy adults, seroconversion following an initial subcutaneous dose of VAQTA was slower than that historically observed following intramuscular administration (Lingl&ouml;f 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Recommended for patients with chronic liver disease; however, these patients may have decreased antibody response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual components. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Packaging may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neomycin: Some products may contain neomycin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Immunization Schedules (ACIP [Kim 2017]; CDC/ACIP [Robinson 2017]). Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions as well as contacts of immunocompromised patients are available from the IDSA (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and is improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]). Due to the long incubation period for hepatitis A (15 to 50 days), unrecognized hepatitis A infection may be present; immunization may not prevent infection in these patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299440\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178818\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8519&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178819\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F936381\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. The safety of vaccination during pregnancy has not been determined, however, the theoretical risk to the infant is expected to be low. Inactivated vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12627365\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if this vaccine is excreted into breast milk. The manufacturer recommends that caution be used if administered to breastfeeding women. Administration does not affect the safety of breastfeeding for the mother or the infant. Breastfeeding infants should be vaccinated according to the recommended schedules (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178821\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests; monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178813\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">As an inactivated virus vaccine, hepatitis A vaccine induces active immunity against hepatitis A virus infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178829\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Protective antibodies develop in 95% of adults after the first dose and in 100% of adults after the second dose of the vaccine; &ge;97% of children and adolescents will be seropositive within 1 month of the first dose and 100% will develop protective antibodies after receiving two doses. The efficacy of preventing hepatitis A disease in children living in highly infected areas is 94% to 100% (CDC 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Protective antibodies induced by the vaccine may persist for &ge;17 years (CDC 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178833\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Havrix Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">720 Elisa units/0.5 mL (0.5 mL): $38.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1440 Elisa units/mL (1 mL): $80.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Vaqta Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 units/0.5 mL (0.5 mL): $38.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 units/mL (1 mL): $81.43</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869385\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Avaxim (AE, AR, AU, BG, CO, CR, CY, DO, EC, GB, GT, HK, HN, ID, IE, IL, KR, KW, LB, LK, NI, PA, QA, SA, SG, SV, TH, VN);</li>\n      <li>Epaxal (AE, BH, CO, GB, IE, IL);</li>\n      <li>HAVpur (DE);</li>\n      <li>Havrix (AT, BE, CH, CL, CN, CR, CZ, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HN, ID, IE, IL, IS, IT, KR, LK, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, PY, RO, RU, SE, SG, SI, SK, SV, TR, TW, UY, VE, VN);</li>\n      <li>Havrix 1440 (AU, BB, BM, BS, BZ, GY, HK, IN, JM, MX, PR, SR, TT);</li>\n      <li>Havrix Junior (BB, BM, BS, BZ, GY, HK, IN, JM, MX, PR, SR, TT);</li>\n      <li>Havrix Monodose (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Havryks (UA);</li>\n      <li>Mevac-A (PH);</li>\n      <li>Vaqta (AE, AU, BH, CN, CR, DE, DO, GB, GT, HN, IE, MX, NI, NZ, PA, QA, SA, SG, SV, TH, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Avaxim (hepatitis A vaccine) [Canadian product monograph]. Lyon, France: Sanofi Pasteur SA; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avaxim pediatric (hepatitis A vaccine) [Canadian product monograph]. Lyon, France: Sanofi Pasteur SA; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bienzle U, Bock HL, Kruppenbacher JP, et al, &ldquo;Immunogenicity of an Inactivated Hepatitis A Vaccine Administered According to Two Different Schedules and the Interference of Other &lsquo;Travelers&rsquo; Vaccines With the Immune Response,&rdquo; <i>Vaccine</i>, 1996, 14(6):501-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/8782347/pubmed\" target=\"_blank\" id=\"8782347\">8782347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for use of hepatitis A vaccine in close contacts of newly arriving international adoptees. <i>MMWR Morb Mortal Wkly Rep</i>. 2009;58(36):1006-1007. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5836a4.htm?s_cid=mm5836a4_e\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5836a4.htm?s_cid=mm5836a4_e</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/19763077/pubmed\" target=\"_blank\" id=\"19763077\">19763077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Morb Mortal Wkly Rep</i>. 2007;56(41):1080-1084.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/17947967/pubmed\" target=\"_blank\" id=\"17947967\">17947967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. <i>Epidemiology and Prevention of Vaccine- Preventable Diseases</i>. Hamborsky J, Kroker A, and Wokfe C, eds. 13th ed., Washington DC: Public Health Foundation, 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/20808459/pubmed\" target=\"_blank\" id=\"20808459\">20808459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fiore AE, Wasley A, Bell BP; Advisory Committee on Immunization Practices (ACIP). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2006;55(RR-7):1-23. <a href=\"http://www.cdc.gov/mmwr/PDF/rr/rr5507.pdf\" target=\"_blank\">http://www.cdc.gov/mmwr/PDF/rr/rr5507.pdf</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/16708058/pubmed\" target=\"_blank\" id=\"16708058\">16708058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gil A, Gonzalez A, Dal-Re R, et al, &ldquo;Interference Assessment of Yellow Fever Vaccine With the Immune Response to a Single-Dose Inactivated Hepatitis A Vaccine (1440 EL.U.): A Controlled Study in Adults,&rdquo; <i>Vaccine</i>, 1996, 14(11):1028-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/8879097/pubmed\" target=\"_blank\" id=\"8879097\">8879097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Havrix (hepatitis A vaccine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jong EC, Kaplan EM, Eves KA, et al, &ldquo;An Open Randomized Study of Inactivated Hepatitis A Vaccine Administered Concomitantly With Typhoid Fever and Yellow Fever Vaccines,&rdquo; J<i> Travel Med</i>, 2002, 9(2):66-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/12044272/pubmed\" target=\"_blank\" id=\"12044272\">12044272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, et al; Advisory Committee on Immunization Practices (ACIP), ACIP Adult Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older&mdash;United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017; 66(5):136-138. doi: 10.15585/mmwr.mm6605e2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lingl&#1255;f T, van Hattum J, Kaplan KM, et al. An Open Study of Subcutaneous Administration of Inactivated Hepatitis A Vaccine (VAQTA) in Adults: Safety, Tolerability, and Immunogenicity [published correction appears in <i>Vaccine</i>. 2001;20(1-2):281]. <i>Vaccine</i>. 2001;19(28-29):3968-3971.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/11427272/pubmed\" target=\"_blank\" id=\"11427272\">11427272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Niu MT, Salive M, Krueger C, et al, &ldquo;Two-Year Review of Hepatitis A Vaccine Safety: Data From the Vaccine Adverse Event Reporting System (VAERS),&rdquo; <i>Clin Infect Dis</i>, 1998, 26(6):1475-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/9636890/pubmed\" target=\"_blank\" id=\"9636890\">9636890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et al; Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Usonis V, Meriste S, Bakasenas V, et al, &ldquo;Immunogenicity and Safety of a Combined Hepatitis A and B Vaccine Administered Concomitantly With Either a Measles-Mumps-Rubella or a Diphtheria-Tetanus-Acellular Pertussis-Inactivated Poliomyelitis Vaccine Mixed With a <i>Haemophilus influenza</i> type b Conjugate Vaccine in Infants Aged 12-18 Months,&rdquo; <i>Vaccine</i>, 2005, 23(20):2602-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/15780442/pubmed\" target=\"_blank\" id=\"15780442\">15780442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Damme P, Banatvala J, Fay O, et al, &ldquo;Hepatitis A Booster Vaccination: Is There a Need?,&rdquo; <i>Lancet</i>, 2003, 362(9389):1065-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hepatitis-a-vaccine-drug-information/abstract-text/14522539/pubmed\" target=\"_blank\" id=\"14522539\">14522539</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vaqta (hepatitis A vaccine, inactivated) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co.; February 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8519 Version 131.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F178838\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F178839\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F178849\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F178840\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F178845\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F178841\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15897460\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15897461\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F178823\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F178810\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F21082722\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734111\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F178827\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F178826\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F10229825\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F178817\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F178830\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F178814\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299440\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F178818\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F178819\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F936381\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F12627365\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F178821\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F178813\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F178829\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F178833\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869385\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8519|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hepatitis-a-vaccine-patient-drug-information\" class=\"drug drug_patient\">Hepatitis A vaccine: Patient drug information</a></li><li><a href=\"topic.htm?path=hepatitis-a-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">Hepatitis A vaccine: Pediatric drug information</a></li></ul></div></div>","javascript":null}